December 22, 2021 | Health Care | Europe | Ended

Vifor Pharma / CSL: Deal Insights

On 14-Dec-21, following nearly two weeks of takeover speculation, Australian biopharma giant CSL entered into a definitive agreement to acquire Swiss speciality pharma company, Vifor Pharma, for USD 11.7bn, or USD 179.25 per share. The deal is structured as an all-cash tender offer and is at a 61% premium to Vifor’s undisturbed price on 1-Dec-21, before the market speculated on a possible bid. Vifor’s board unanimously recommends the offer, which is subject to regulatory approvals and an 80% minimum acceptance threshold. Patinex (private), Vifor’s largest shareholder ...

How to Access this Report

Please contact us to request access to this report.


Share this article


Back to top of page